ArticleCureus2026
Drug-Induced Cholestasis Secondary to Meropenem in an Elderly Patient: Report of A Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meropenem is a broad-spectrum carbapenem antibiotic commonly used in hospitals to treat moderate-to-severe infections. Although rare, meropenem can cause drug-induced liver disease, including mild transaminase elevation, cholestasis, or hepatic failure. This report presents an 80-year-old woman admitted after a mechanical fall and diagnosed with a catheter-associated urinary tract infection. Intravenous meropenem was initiated following urine culture confirmation of Citrobacter koseri in the context of worsening confusion and elevated inflammatory markers. Six days after starting meropenem, the patient developed generalised weakness and mild pruritus. Liver function tests showed significant abnormalities: alkaline phosphatase (ALP) 1450 U/L and alanine transaminase (ALT) 415 U/L. Liver function improved after meropenem was discontinued. The pattern of injury was consistent with cholestatic drug-induced liver injury (DILI) (R-value = 1), and an updated Roussel Uclaf Causality Assessment Method (RUCAM) score of 8 indicated a probable causal relationship with meropenem. This case highlights the importance of considering DILI, even with short-term antibiotic use, especially in elderly patients. Routine monitoring of liver function is recommended for those receiving meropenem. Early recognition and prompt withdrawal of the offending agent are essential for clinical improvement and prevention of complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.